Kelly Dooley, MD, PhD

Faculty

Titles:

Associate Professor, Medicine and Pharmacology and Molecular Sciences

Email:

kdooley1@jhmi.edu

SciVal:

SciVal Link

Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.

Categories

Events

«

January 2019

»
S
M
T
W
T
F
S
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·

Projects

mHealth for improved TB contact investigation...

This multicenter randomized study is evaluating the implementation, effectiveness, cost-effectiveness, and population-level...

Read More

TB Modeling and Analysis Consortium (TB MAC)

Dr. Dowdy serves on the steering committee of an international consortium of TB modelers that aims to improve approaches to TB...

Read More

Comparative Effectiveness/Implementation of...

This cluster-randomized trial in 56 rural primary care clinics compares the effectiveness and implementation of three strategies...

Read More